This potentially could be through the use of the FDA approved drug, Lumacaftor (see Chapter “Cystic Fibrosis: a clinical view”), which improves folding and processing of F508del-CFTR to the plasma membrane, as well as Ivacaftor to improve channel activity. This evidence concerns the gene CFTR and cystic fibrosis.